CTOR - NASDAQ

Citius Oncology, Inc.

CTOR·NASDAQ

$0.77

-1.9%

HealthcareDrug Manufacturers - General

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$71.14M

EPS-0.3400

P/E Ratio-2.25

Earnings Date08/18/2026

ctor

Total Assets

Last Annual Value

100.94M

3-Year CAGR

33%

5-Year CAGR

19%

10-Year CAGR

Adjust for Inflation

Citius Oncology, Inc. Competitors Analysis of Total Assets

CTOR · NASDAQ

Company	Total Assets	CAGR 3Y	CAGR 5Y	CAGR 10Y
Citius Oncology, Inc. NASDAQ:CTOR	100.94M	28.4%	N/A	N/A
Fate Therapeutics, Inc. NASDAQ:FATE	318.94M	-14.3%	-19.1%	12.9%
Seres Therapeutics, Inc. NASDAQ:MCRB	138.19M	-27.2%	-17.2%	-6.6%
Acumen Pharmaceuticals, Inc. NASDAQ:ABOS	122.83M	-26.6%	-11.8%	N/A
Atossa Therapeutics, Inc. NASDAQ:ATOS	47.61M	-20.9%	-19.5%	27.7%
Greenwich LifeSciences, Inc. NASDAQ:GLSI	-6.74M	N/A	N/A	N/A
AVITA Medical, Inc. NASDAQ:RCEL	56.39M	-20.4%	-13.4%	22.1%
Rapid Micro Biosystems, Inc. NASDAQ:RPID	74.85M	-19.5%	-20.9%	N/A
Tevogen Bio Holdings Inc. NASDAQ:TVGN	3.46M	-14.3%	-14.7%	N/A
C4 Therapeutics, Inc. NASDAQ:CCCC	359.07M	-1.6%	-6.7%	N/A
Spero Therapeutics, Inc. NASDAQ:SPRO	68.92M	-27.7%	-16.6%	17.5%

Citius Oncology, Inc. Fair Value Envelope

CTOR · NASDAQ

Our analysis suggests that CTOR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $0.7651, this represents a potential HIDDEN relative to our calculated worth for Citius Oncology, Inc..

HIDDEN

Intrinsic Value

Current Price: $0.7651

Related Guides

Blog Categories

Continue your CTOR research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.